论文部分内容阅读
1文献来源Paik PK,Felip E,Veillon R,et al.Tepotinib in non⁃small⁃cell lung cancer with MET exon 14 skipping mutations[J].N Engl J Med,2020,383(10):931-943.2证据水平2b。3背景约3%~4%非小细胞肺癌(non⁃small⁃cell lung cancer,NSCLC)患者具有MET 14外显子跳读突变。Tepotinib是高选择性口服MET抑制剂,既往研究表明,